We use cookies to personalise the web experience for you. By using www.helgilibrary.com, you agree to our use of cookies.
Some cookies are also used by Google Analytics, which anonymously tracks visitors and helps us to analyse how users use our website. Read more

Amgen Czech Republic

Pharmaceutical > Czech Republic > Amgen Czech Republic
Change Company
Amgen Czech Republic

Amgen Czech Republic is a Czech Republic-based subsidiary of the global pharmaceutical company Amgen. Amgen entered the Czech market in May 2004 folowing the entrance of the country into the EU. Now, the Czech subsidiary employes around 60 people with sales accounting for over USD 20 mil. Amgen (Applied Molecular Genetics) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Located in the Conejo

Read more »
Amgen Czech Republic is a Czech Republic-based subsidiary of the global pharmaceutical company Amgen. Amgen entered the Czech market in May 2004 folowing the entrance of the country into the EU. Now, the Czech subsidiary employes around 60 people with sales accounting for over USD 20 mil. Amgen (Applied Molecular Genetics) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Located in the Conejo Valley, Amgen is the world's largest independent biotechnology firm. In 2013, the company's largest selling product lines were Neulasta/Neupogen, two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy; and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases

Buy all financials of Amgen Czech Republic

from $199 /month

Buy annual subscriptions for all our products.

summary Unit
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

income statement

Sales CZK mil
Gross Profit CZK mil
EBIT CZK mil
Net Profit CZK mil
ROE %
EBIT Margin %
Net Margin %
Employees
...             422 416 468 637 604    
...             177 154 159 169 159    
...             56.3 35.0 38.9 52.5 44.3    
...             46.2 28.3 28.7 40.5 35.8    
...             31.6% 15.4% 15.8% 21.7% 18.4%    
...             13.3% 8.40% 8.32% 8.25% 7.34%    
...             10.9% 6.81% 6.14% 6.36% 5.93%    
              72.0 66.0 67.0 65.0 65.0    

balance sheet

...             227 259 218 267 276    
...             6.77 5.13 4.91 2.67 1.43    
...             219 253 213 263 274    
...             169 198 167 207 183    
...             57.1 60.8 51.9 60.3 93.3    
...             0.029 0.029 0.029 0.000 0.000    
...             55.7 59.2 51.8 59.7 92.9    
...             0.000 0.000 -0.005 0.709 1.53    
...             0.000% 0.000% -0.133% 18.6% 38.7%    
... ... ... ... ... ... ... ... ... 1,890% 11.3% 0.592%   ...

cash flow

... ...           52.0 20.0 81.2 -43.7 130    
... ...           -52.0 -20.0 -21.0 44.7 -69.9    
... ...           0.000 0.000 -60.0 -0.028 -60.0    
... ...           0.000 0.000 0.251 0.926 -0.159    

Download Data
income statement Unit
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

income statement

Sales CZK mil
Cost of Goods & Services CZK mil
Gross Profit CZK mil
Staff Cost CZK mil
Other Cost CZK mil
EBITDA CZK mil
Depreciation CZK mil
EBIT CZK mil
Financing Cost CZK mil
Extraordinary Cost CZK mil
Pre-Tax Profit CZK mil
Tax CZK mil
Minorities CZK mil
Net Profit CZK mil
Dividends CZK mil
...             422 416 468 637 604    
...             245 262 309 467 445    
...             177 154 159 169 159    
...             111 106 102 98.2 96.4    
...             7.27 11.1 15.8 16.7 16.4    
...             58.3 37.3 41.1 54.4 46.3    
...             2.02 2.31 2.21 1.94 1.93    
...             56.3 35.0 38.9 52.5 44.3    
...             -0.196 -0.315 0.274 2.25 0.330    
...             0.000 0.000 0.000 0.000 0.000    
...             56.5 35.3 38.6 50.2 44.0    
...             10.3 6.94 7.90 9.76 8.17    
...             0.000 0.000 0.000 0.000 0.000    
...             46.2 28.3 28.7 40.5 35.8    
... ... ... ... ... ... ... ... ... ... ... 0.000   ...

growth rates

... ...           17.8% -1.40% 12.4% 36.0% -5.06%    
... ...           8.84% -1.44% 0.493% -2.18% -1.76%    
... ...           50.4% -36.1% 10.4% 32.3% -15.0%    
... ...           56.9% -37.9% 11.3% 34.9% -15.5%    
... ...           55.9% -37.5% 9.53% 30.0% -12.4%    
... ...           57.1% -38.7% 1.42% 40.8% -11.4%    

ratios

...             31.6% 15.4% 15.8% 21.7% 18.4%    
... ...           48.3% 26.3% 33.8% 44.9% 36.6%    
...             41.9% 37.0% 33.9% 26.6% 26.3%    
...             13.8% 8.95% 8.79% 8.55% 7.66%    
...             13.3% 8.40% 8.32% 8.25% 7.34%    
...             10.9% 6.81% 6.14% 6.36% 5.93%    
... ... ... ... ... ... ... ... ... ... ... 0.000%   ...
... ... ... ... ... ... ... ... ... 1,890% 11.3% 0.592%   ...
...             0.000 0.000 -0.005 0.709 1.53    

Download Data
balance sheet Unit
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

balance sheet

...             6.77 5.13 4.91 2.67 1.43    
...             5.47 3.81 2.82 2.67 1.43    
...             1.29 1.32 1.25 1.81 1.35    
... ... ... ... ... ... ... ... ... ... 0.857 0.081    
...             219 253 213 263 274    
...             0.000 0.000 0.000 0.000 0.000    
...             99.5 112 48.4 137 81.9    
...             0.000 0.000 0.251 1.18 1.02    
...             227 259 218 267 276    
...             169 198 167 207 183    
...             0.000 0.000 0.000 0.000 0.000    
...             57.1 60.8 51.9 60.3 93.3    
...             0.029 0.029 0.029 0.000 0.000    
...             0.000 0.000 0.029 0.000 0.000    
...             0.000 0.000 0.000 0.000 0.000    
...             55.7 59.2 51.8 59.7 92.9    
...             0.000 0.000 0.000 39.8 71.8    
...             7.08 0.645 0.029 12.6 14.4    
...             1.27 1.54 0.000 0.000 0.000    
...             227 259 218 267 276    

growth rates

... ...           36.5% 14.1% -15.6% 22.4% 3.28%    
... ...           37.5% 16.7% -15.8% 24.3% -11.7%    
... ...           ... ... ... -17,482% 83.3%    
... ... ... ... ... ... ... ... ... ... 137,021% 80.5%   ...

ratios

...             0.000 0.000 0.029 39.8 71.8    
...             0.000 0.000 -0.222 38.6 70.7    
...             92.4 111 48.4 124 67.4    
...             99.2 117 53.3 127 68.9    
...             0.000% 0.000% -0.133% 18.6% 38.7%    
... ... ... ... ... ... ... ... ... 1,890% 11.3% 0.592%   ...

Download Data
cash flow Unit
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

cash flow

...             46.2 28.3 28.7 40.5 35.8    
...             2.02 2.31 2.21 1.94 1.93    
... ...           11.5 8.40 -12.8 -10.3 35.2    
... ...           -7.70 -19.0 63.1 -75.8 56.8    
... ...           52.0 20.0 81.2 -43.7 130    
... ...           -2.00 -1.00 -1.15 -0.543 -0.695    
... ...           -50.0 -19.0 -19.8 45.2 -69.3    
... ...           -52.0 -20.0 -21.0 44.7 -69.9    
... ... ... ... ... ... ... ... ... ... ... ...    
... ... ... ... ... ... ... ... ... ... ... ...    
... ...           0.000 0.000 0.029 39.7 32.0    
... ...           0.000 0.000 -60.0 -0.028 -60.0    
... ...           0.000 0.000 0.251 0.926 -0.159    

ratios

...             86.0 98.3 37.8 78.4 49.5    
...             0.000 0.000 0.000 0.000 0.000    
...             10.5 0.898 0.034 9.84 11.8    
...             75.5 97.4 37.7 68.6 37.6    
...             48.2 30.6 31.0 42.4 37.8    
... ...           0.000 0.000 60.3 0.954 59.8    

Download Data
other data Unit
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

other data

...             23.5% 11.7% 12.0% 16.7% 13.2%    
...             41.9% 37.0% 33.9% 26.6% 26.3%    
              72.0 66.0 67.0 65.0 65.0    
...             7,282 6,827 6,457 5,890 5,178    
...             128,795 133,538 126,332 125,883 123,604    
...             30.4% 27.7% 23.7% 16.8% 17.2%    
...             18.2% 19.7% 20.4% 19.4% 18.6%    
...             190 184 176 176 166    
...             233 232 292 460 438    
... ...           0.474% 0.240% 0.245% 0.085% 0.115%    

Download Data
Comparison of 9 Companies in Czech Pharmaceutical Companies

This Annual Statistical Dossier offers a comparison of 9 companies from Czech Pharmaceutical Companies from 2000 to 2017 on an annual basis. The report can be downloaded as an Excel file.

You will find here the key numbers from the company's balance sheet, income statement, cash flow and the main ratios related to the firm's business.

The file

Read more »

This Annual Statistical Dossier offers a comparison of 9 companies from Czech Pharmaceutical Companies from 2000 to 2017 on an annual basis. The report can be downloaded as an Excel file.

You will find here the key numbers from the company's balance sheet, income statement, cash flow and the main ratios related to the firm's business.

The file contains data of following companies:

If you are only interested in particular areas of the company's business, you can find and download specific indicators from the company's Corporate Profile, or specific charts from the company's Chart Section.

Download a sample excel file attached to see more details. On purchase, the hidden cells will be unlocked and all available data wll be visible.

Amgen Czech Republic in Numbers

This Annual Statistical Dossier offers a summary of Amgen Czech Republic's performance between 2004 and 2017 on an annual basis. The report can be downloaded as an Excel file.

You will find here the key numbers from the company's balance sheet, income statement, cash flow and the main ratios related to the firm's business.

If you are only interested

Read more »

This Annual Statistical Dossier offers a summary of Amgen Czech Republic's performance between 2004 and 2017 on an annual basis. The report can be downloaded as an Excel file.

You will find here the key numbers from the company's balance sheet, income statement, cash flow and the main ratios related to the firm's business.

If you are only interested in particular areas of the company's business, you can find and download specific indicators from the company's Corporate Profile, or specific charts from the company's Chart Section.

If you are interested in the company’s quarterly figures, please refer to the company’s Quarterly Statistical Dossier.

Amgen Czech Republic at a Glance

Amgen Czech Republic is a Czech Republic-based subsidiary of the global pharmaceutical company Amgen. Amgen entered the Czech market in May 2004 folowing the entrance of the country into the EU. Now, the Czech subsidiary employes around 60 people with sales accounting for over USD 20 mil. Amgen (Applied Molecular Genetics) is an American multinational biopharmaceutical

Read more »

Amgen Czech Republic is a Czech Republic-based subsidiary of the global pharmaceutical company Amgen. Amgen entered the Czech market in May 2004 folowing the entrance of the country into the EU. Now, the Czech subsidiary employes around 60 people with sales accounting for over USD 20 mil. Amgen (Applied Molecular Genetics) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Located in the Conejo Valley, Amgen is the world's largest independent biotechnology firm. In 2013, the company's largest selling product lines were Neulasta/Neupogen, two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy; and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

This report offers a summary of the company's performance in 2005-2012. You will find here all the key numbers from the company's balance sheet, income statement and cash flow on the annual, in the local currency as well as in USD

Amgen Czech Republic in Numbers

Amgen Czech Republic is a Czech Republic-based subsidiary of the global pharmaceutical company Amgen. Amgen entered the Czech market in May 2004 folowing the entrance of the country into the EU. Now, the Czech subsidiary employes around 60 people with sales accounting for over USD 20 mil. Amgen (Applied Molecular Genetics) is an American multinational biopharmaceutical

Read more »

Amgen Czech Republic is a Czech Republic-based subsidiary of the global pharmaceutical company Amgen. Amgen entered the Czech market in May 2004 folowing the entrance of the country into the EU. Now, the Czech subsidiary employes around 60 people with sales accounting for over USD 20 mil. Amgen (Applied Molecular Genetics) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Located in the Conejo Valley, Amgen is the world's largest independent biotechnology firm. In 2013, the company's largest selling product lines were Neulasta/Neupogen, two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy; and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

This excel file offers a summary of the company's performance in 2005-2012. You will find here all the key numbers from the company's balance sheet, income statement and cash flow on the annual, in the local currency as well as in USD

Based on a comparison of 9 firms among Czech Pharmaceutical Companies, Sanofi-Aventis Czech Republic had the biggest debt relative to its equity at the end of 2017 followed by Bayer Czech Republic and Pfizer Czech Republic.

Sanofi-Aventis Czech

Read more »

Based on a comparison of 9 firms among Czech Pharmaceutical Companies, Sanofi-Aventis Czech Republic had the biggest debt relative to its equity at the end of 2017 followed by Bayer Czech Republic and Pfizer Czech Republic.

Sanofi-Aventis Czech Republic net debt reached CZK 774 mil. and accounted for 103% of equity at the end of 2017. The ratio is down 55.7% when compared to the previous year. Historically, the firm’s net debt to equity reached an all time high of 336% in 2004 and an all time low of 57.8% in 2015.

When compared to EBITDA, net debt amounted to 15.3x at the end of the year. The ratio reached an all time high of 29.5x in 2004 and an all time low of 4.16x in 2005.

Comparing Sanofi-Aventis Czech Republic with its closest peers, Bayer Czech Republic posted net debt to equity of 94.4% and 2.49x when compared to EBITDA at the end of 2017. Pfizer Czech Republic ended the year 2016 with a net debt at 24.2% of equity and 2.10x when compared to its EBITDA while Novartis Czech Republic had net debt at 7.85% of equity and 0.371x to EBITDA at the end of the year.

You can see all the companies net debt/equity data on the Net Debt/Equity indicator page or you can download a special statistical dossier on the Czech Pharmaceutical Companies in the reports section.

Based on a comparison of 9 firms among Czech Pharmaceutical Companies, Bayer Czech Republic generated the highest earnings before interest cost, taxes and depreciation (so called EBITDA) in 2017 followed by Pfizer Czech Republic and Novartis Czech Republic.

Read more »

Based on a comparison of 9 firms among Czech Pharmaceutical Companies, Bayer Czech Republic generated the highest earnings before interest cost, taxes and depreciation (so called EBITDA) in 2017 followed by Pfizer Czech Republic and Novartis Czech Republic.

Bayer Czech Republic made EBITDA of CZK 158 mil, down 32.3% compared to the previous year. Historically, the firm’s EBITDA reached an all time high of CZK 233 mil in 2016 and an all time low of CZK -10.0 mil in 2007. The average profit in the last five years amounted to CZK 167 mil.

The company generated an average EBITDA margin of 4.11% for its shareholders in the last five years with a maximum of 5.38% and a minimum of 3.53%.

Comparing Bayer Czech Republic with its closest peers, Pfizer Czech Republic generated EBITDA of CZK 156 mil with a EBITDA margin of 4.36% in 2017, Novartis Czech Republic grossed CZK 138 mil (EBITDA margin of 2.18%) and GlaxoSmithKline Czech Republic announced a profit of CZK 97.4 mil translating into a margin of 3.36%.

You can see all the companies ebitda data on the EBITDA indicator page or you can download a special statistical dossier on the Czech Pharmaceutical Companies in the reports section.

Based on a comparison of 9 firms among Czech Pharmaceutical Companies, Amgen Czech Republic generated the highest EBIIDA Margin in 2017 followed by Pfizer Czech Republic and Merck Czech Republic.

Amgen Czech Republic made EBITDA of CZK 49.0

Read more »

Based on a comparison of 9 firms among Czech Pharmaceutical Companies, Amgen Czech Republic generated the highest EBIIDA Margin in 2017 followed by Pfizer Czech Republic and Merck Czech Republic.

Amgen Czech Republic made EBITDA of CZK 49.0 mil, which translates into EBITDA margin of 11.8%. Historically, the firm’s margin reached an all time high of 13.8% in 2011 and an all time low of 6.20% in 2016. The average EBITDA margin in the last five years amounted to 8.59%.

Comparing Amgen Czech Republic with its closest peers, Pfizer Czech Republic generated EBITDA of CZK 156 mil with a EBITDA margin of 4.36% in 2017, Merck Czech Republic grossed CZK 72.8 mil (EBITDA margin of 4.00%) and Bayer Czech Republic announced a profit of CZK 158 mil translating into a margin of 3.77%.

You can see all the companies ebitda margin data on the EBITDA Margin indicator page or you can download a special statistical dossier on the Czech Pharmaceutical Companies in the reports section.

Based on a comparison of 9 firms among Czech Pharmaceutical Companies, Sanofi-Aventis Czech Republic generated the highest sales in 2017 followed by Novartis Czech Republic and Bayer Czech Republic.

Sanofi-Aventis Czech Republic made total sales

Read more »

Based on a comparison of 9 firms among Czech Pharmaceutical Companies, Sanofi-Aventis Czech Republic generated the highest sales in 2017 followed by Novartis Czech Republic and Bayer Czech Republic.

Sanofi-Aventis Czech Republic made total sales of CZK 7,268 mil, up 8.47% compared to the previous year. Historically, the firm’s revenues an all time high of CZK 7,525 mil in 2010 and an all time low of CZK 2,045 mil in 2004.

The average sales growth in the last five years amounted to 0.118%.

Comparing Sanofi-Aventis Czech Republic with its closest peers, Novartis Czech Republic generated a sales of CZK 6,312 mil average sales growth 9.94% in 2017, Bayer Czech Republic sold products and services worth CZK 4,180 mil (5-year growth of 5.19%) and Pfizer Czech Republic announced revenues of CZK 3,586 mil translating into average nominal growth of 5.19% in the last five years.

You can see all the companies sales data on the Sales indicator page or you can download a special statistical dossier on the Czech Pharmaceutical Companies in the reports section.

See all charts of the company »
Amgen CR's net profit rose 20.0% to CZK 37.8 mil in 2017
Amgen CR's employees rose 7.94% to 68.0 in 2017
Amgen CR's ROCE fell 20.6% to 14.2% in 2017
Amgen CR's Total Cash From Operations rose 1,003% to CZK 118 mil in 2017
Amgen CR's Net Margin rose 80.1% to 9.06% in 2017
Amgen CR's Net Debt/EBITDA rose 16.7% to -0.006 in 2017
Amgen CR's Capital Expenditures fell 66.3% to CZK 0.135 mil in 2017
Amgen CR's Cash & Cash Equivalents rose 5.20% to CZK 0.283 mil in 2017